Subcutaneous Risankizumab Induction Improved Outcomes in Crohn's Disease

(MedPage Today) -- Subcutaneous risankizumab (Skyrizi) induction therapy significantly improved clinical remission and endoscopic response rates in patients with moderately to severely active Crohn's disease, results from the phase III AFFIRM trial...

Read it at MedPage Today ↗

← Front page